Quote this publication Share Print

NEOFORDEX (dexamethasone), glucocorticoid

ONCOLOGY - NEW PRESENTATION
Opinions on drugs - Posted on Jul 05 2017

Reason for request

Inclusion

Minor clinical added value for this medicine based on dexamethasone at 40 mg compared to DECTANCYL (dexamethasone 0.5 mg) in the context of symptomatic multiple myeloma therapeutic protocols

   

  • NEOFORDEX has marketing authorisation for adults, in combination, for the treatment of symptomatic multiple myeloma.
  • The use of corticosteroid therapy has been established for many decades in haematological malignancies and especially multiple myeloma.
  • The dexamethasone form of NEOFORDEX 40 mg is more suitable than the 0.5 mg form.

 


Clinical Benefit

Substantial

-


Clinical Added Value

minor

-


Contact Us

Évaluation des médicaments